Prospective Tumor Response Evaluation

Prospective Evaluation of Tumor Response to Cancer Treatment Therapies

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02787954

Acronym

Liver

Enrollment

Registered

2016-06-01

Start date

2016-01-31

Completion date

2017-04-30

Last updated

2018-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Cancer, Metastatic Liver Cancer

Brief summary

The purpose of this study is to determine if MRI imaging can detect genetic, proteomic, and metabolomic characteristics of liver tumors. The study also aims to determine if these imaging characteristics are correlated with clinical outcomes.

Detailed description

For each treatment arm, pre-procedural MRI and post procedural MRI will be obtained. Pre-procedural biopsies will be obtained, if possible. Pretreatment genetic expression, proteomic, or metabolomic patterns from the tumor samples will be assessed. Imaging characteristics from tumors will be extracted using automated software-the study will apply a computational analysis system with the capability to extract and analyze imaging characteristics and correlate them to genetic expression, proteomic, and metabolomic tumor characteristics. Imaging findings will be correlated to clinical outcomes and genetic, proteomic, and metabolomic findings to determine association. Imaging findings and genomic, proteomic, and metabolomic tumor characteristics will be correlated to clinical outcomes (time to recurrence, overall survival, 3-month, 6-month, and 1-year survival).

Interventions

PROCEDURETACE

Procedure for giving chemotherapy directly to tumor cells.

PROCEDUREY-90

Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.

PROCEDUREMWA

Using heat to kill tumor cells.

PROCEDUREIRE

Using energy to disrupt tumor cell activity, thereby causing cellular death.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Diagnosis or suspicion of primary or metastatic liver cancer deemed eligible for TACE, Y-90, percutaneous ablation, and /or electroporation.

Exclusion criteria

* Any reason MRI cannot be obtained.

Design outcomes

Primary

Measure	Time frame	Description
Time to progression	1 month to 3 years	Time from initial treatment to progression as defined by RECIST criteria.

Secondary

Measure	Time frame	Description
1 year survival	1 year	Number of patients alive 1 year after treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026